AI Engines For more Details: Perplexity Kagi Labs You
Detoxification: Manjistha is considered a powerful blood purifier in Ayurveda. It is believed to help detoxify the blood and remove toxins from the body, promoting overall health and well-being. Manjistha may support liver function and enhance the body's natural detoxification processes.
Anti-inflammatory Properties: Manjistha contains bioactive compounds such as rubiadin and purpurin, which have been studied for their anti-inflammatory effects. Manjistha may help reduce inflammation in the body and alleviate symptoms of inflammatory conditions such as arthritis, rheumatism, and inflammatory bowel disease (IBD).
Antioxidant Protection: Manjistha is rich in antioxidants, which help neutralize free radicals and protect cells from oxidative damage. Antioxidants may help reduce the risk of chronic diseases such as cardiovascular disease, cancer, and neurodegenerative disorders.
Skin Health: Manjistha is commonly used in Ayurvedic skincare formulations due to its ability to promote radiant and healthy skin. It may help improve complexion, reduce acne and blemishes, and alleviate skin conditions such as eczema and psoriasis. Manjistha may also have wound-healing properties that could help promote faster healing of cuts, bruises, and other skin injuries.
Urinary Health: Manjistha has diuretic properties and may help promote urinary health by increasing urine production and flushing out toxins and waste products from the body. It may help prevent urinary tract infections (UTIs) and kidney stones by promoting urine flow and inhibiting the growth of pathogenic bacteria in the urinary tract.
Menstrual Health: In Ayurveda, Manjistha is used to support menstrual health and alleviate symptoms of menstrual disorders such as irregular periods, menstrual cramps, and excessive bleeding. It may help regulate hormonal balance, reduce inflammation in the reproductive organs, and promote a healthy menstrual cycle.
Liver Support: Manjistha is believed to support liver health and function by promoting detoxification and reducing oxidative stress. It may help protect the liver from damage caused by toxins, alcohol, or certain medications, and improve liver function tests.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.5 | 1.3 | -1.6 |
ADHD | 1 | 0.7 | 0.43 |
Allergic Rhinitis (Hay Fever) | 0 | 0 | |
Allergies | 0.8 | 1.9 | -1.37 |
Allergy to milk products | 1.2 | -1.2 | |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 1.7 | 2.2 | -0.29 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 2.6 | -3.33 |
Ankylosing spondylitis | 0.7 | 1.2 | -0.71 |
Anorexia Nervosa | 0.7 | 0.2 | 2.5 |
Asthma | 0.9 | 0.5 | 0.8 |
Atherosclerosis | 1.5 | 0.2 | 6.5 |
Atrial fibrillation | 0.5 | 0.5 | 0 |
Autism | 2.5 | 3.1 | -0.24 |
Bipolar Disorder | 1 | 1.7 | -0.7 |
Brain Trauma | 0 | 0 | |
Carcinoma | 0.5 | 0.5 | 0 |
Celiac Disease | 1.5 | 1 | 0.5 |
Cerebral Palsy | 0.3 | -0.3 | |
Chronic Fatigue Syndrome | 0.5 | 1.7 | -2.4 |
Chronic Kidney Disease | 1.1 | -1.1 | |
Chronic Urticaria (Hives) | 1.8 | 1.8 | |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.2 | |
Colorectal Cancer | 1.3 | 1.2 | 0.08 |
COVID-19 | 3 | 3.3 | -0.1 |
Crohn's Disease | 1.6 | 1.3 | 0.23 |
Depression | 3.6 | 2 | 0.8 |
Dermatomyositis | 1.7 | -1.7 | |
Eczema | 0 | 1.2 | 0 |
Endometriosis | 0.5 | 0.5 | |
Eosinophilic Esophagitis | 1.9 | -1.9 | |
Epilepsy | 3 | 0.8 | 2.75 |
Fibromyalgia | 0.7 | 0.7 | |
Functional constipation / chronic idiopathic constipation | 1 | 1.9 | -0.9 |
gallstone disease (gsd) | 0.5 | -0.5 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.6 | 0.17 |
Generalized anxiety disorder | 0 | 0 | |
giant cell arteritis | 0 | 0 | |
Gout | 0.4 | 1.2 | -2 |
Graves' disease | 0.2 | 2.4 | -11 |
Hashimoto's thyroiditis | 0.5 | 0.3 | 0.67 |
Heart Failure | 0.2 | 0.2 | |
Hidradenitis Suppurativa | 0.5 | -0.5 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.5 | |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
hyperglycemia | 0.9 | 0.9 | |
Hyperlipidemia (High Blood Fats) | 1.2 | 1 | 0.2 |
hypertension (High Blood Pressure | 1.7 | 0.8 | 1.13 |
Hypoxia | 0.3 | -0.3 | |
IgA nephropathy (IgAN) | 0.7 | -0.7 | |
Inflammatory Bowel Disease | 2 | 1.2 | 0.67 |
Insomnia | 0.5 | -0.5 | |
Irritable Bowel Syndrome | 1.3 | 1.6 | -0.23 |
Juvenile idiopathic arthritis | 1.1 | -1.1 | |
Liver Cirrhosis | 0.8 | 0.8 | 0 |
Long COVID | 1.4 | 3.4 | -1.43 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.6 | 0.3 | 1 |
ME/CFS with IBS | 0.5 | 0.5 | |
Metabolic Syndrome | 3.3 | 2.1 | 0.57 |
Mood Disorders | 3.8 | 3.8 | 0 |
multiple chemical sensitivity [MCS] | 0.3 | -0.3 | |
Multiple Sclerosis | 2 | 1.4 | 0.43 |
Multiple system atrophy (MSA) | 0.2 | 0.9 | -3.5 |
Neuropathy (all types) | 1.7 | 1.5 | 0.13 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 1.1 | -1.2 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 0.5 | 1.8 |
Obesity | 3.2 | 1.6 | 1 |
obsessive-compulsive disorder | 1.1 | 1.1 | |
Osteoarthritis | 0.2 | 0.5 | -1.5 |
Osteoporosis | 1.2 | 2.7 | -1.25 |
Parkinson's Disease | 1 | 1.8 | -0.8 |
Polycystic ovary syndrome | 0.3 | 1 | -2.33 |
Premenstrual dysphoric disorder | 1.2 | 1.2 | |
Psoriasis | 2.6 | 0.8 | 2.25 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | -1.3 | |
Rosacea | 1.7 | -1.7 | |
Schizophrenia | 0.2 | 2.8 | -13 |
sensorineural hearing loss | 0.5 | 0.5 | |
Sjögren syndrome | 1 | 0.5 | 1 |
Sleep Apnea | 0.5 | 1 | -1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | -0.5 | |
Stress / posttraumatic stress disorder | 0.6 | 0.8 | -0.33 |
Systemic Lupus Erythematosus | 1.4 | 1.2 | 0.17 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 1.1 | 0.6 | 0.83 |
Type 2 Diabetes | 3.1 | 2.1 | 0.48 |
Ulcerative colitis | 2.8 | 1.5 | 0.87 |
Unhealthy Ageing | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.